Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results

Xeris Biopharma (NASDAQ:XERS) released its quarterly earnings data on Monday. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03, reports. The business had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Financial self-sustainability achieved — Xeris reported full-year net income and ~$59.4M adjusted EBITDA in 2025 and guided 2026 revenue of $375–$390M while expecting to remain adjusted EBITDA positive.
• Recorlev is the primary growth engine, ending 2025 at ~700 patients (nearly double year‑over‑year) with FY revenue of $139.3M, and the company nearly doubled its commercial team in January to accelerate adoption with impacts expected notably in H2 2026.
• Xeris filed a patent infringement lawsuit against two ANDA filers to defend Recorlev and points to four Orange Book‑listed patents through March 2040 and orphan exclusivity to end of 2028, but litigation timelines are uncertain and could create a multi‑year overhang.
• The pipeline priority XP‑8121 (once‑weekly subcutaneous levothyroxine) is planned to start Phase 3 in H2 2026, targets an estimated 3–5M patients with absorption issues, and is modeled for potential peak sales of $1–$3B, with R&D budget to increase by about $25M to support the program.
• The commercial portfolio is durable — Gvoke and Keveyis delivered steady contributions, gross margin improved to ~85% for 2025 (87% in Q4), and management expects further margin improvement and continued operating leverage despite planned SG&A investments (~$45M) to scale Recorlev.

Xeris Biopharma Trading Down 1.6%

Shares of NASDAQ XERS traded down $0.10 during mid-day trading on Monday, reaching $6.02. The company had a trading volume of 5,043,164 shares, compared to its average volume of 2,062,694. The stock has a market cap of $998.86 million, a price-to-earnings ratio of -60.19 and a beta of 0.52. Xeris Biopharma has a 52 week low of $3.59 and a 52 week high of $10.08. The business’s 50-day moving average is $7.23 and its 200-day moving average is $7.64.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on XERS shares. Piper Sandler upped their price objective on Xeris Biopharma from $6.00 to $8.00 and gave the company a “neutral” rating in a research report on Friday, November 7th. Wall Street Zen lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a report on Saturday, November 8th. Barclays began coverage on Xeris Biopharma in a research report on Monday, December 8th. They issued an “overweight” rating and a $9.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, January 21st. Finally, Oppenheimer restated an “outperform” rating and issued a $18.00 target price on shares of Xeris Biopharma in a report on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Xeris Biopharma has a consensus rating of “Moderate Buy” and a consensus price target of $10.08.

Xeris Biopharma News Roundup

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q4 results beat on EPS and management raised FY‑2026 revenue guidance — Xeris reported $0.06 EPS vs. $0.03 consensus and issued revenue guidance of $375.0M–$390.0M (above the $370.3M consensus), a constructive top‑line outlook that can support valuation and growth expectations. Press Release
• Positive Sentiment: HC Wainwright reaffirmed a Buy and set a $10 price target — analyst backing and a mid‑double‑digit upside target (about 66% from current levels) provide a bullish catalyst if sentiment improves. HC Wainwright Reaffirmation
• Neutral Sentiment: Conference call / transcripts available — management commentary and the Q&A will be key for clarity on margin drivers, growth cadence, and timing of any product/lifecycle initiatives. Earnings Call Transcript
• Neutral Sentiment: Press coverage and analyst notes summarize the results — most outlets note the EPS beat but highlight that reported revenue of $85.81M was just shy of the $86.0M estimate (a mixed signal). Zacks Coverage
• Negative Sentiment: Recurlev/Recorlev exclusivity and valuation risk — recent coverage highlights Xeris’ efforts to defend Recorlev exclusivity; litigation/regulatory outcomes are uncertain and could materially affect future revenue. Yahoo Valuation / Exclusivity Article
• Negative Sentiment: Guidance omitted EPS detail and revenue miss vs. quarterly estimate — while revenue guidance was raised, management didn’t provide clear EPS guidance in the release and quarter revenue was a touch below expectations, leaving short‑term profitability visibility limited. No link

Insider Transactions at Xeris Biopharma

In other Xeris Biopharma news, insider Kevin Mcculloch sold 15,000 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $8.00, for a total transaction of $120,000.00. Following the transaction, the insider directly owned 1,685,426 shares in the company, valued at $13,483,408. This represents a 0.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director John Johnson sold 135,400 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.22, for a total transaction of $977,588.00. Following the transaction, the director directly owned 698,083 shares in the company, valued at $5,040,159.26. This trade represents a 16.25% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 223,641 shares of company stock valued at $1,628,285 in the last ninety days. Corporate insiders own 6.47% of the company’s stock.

Institutional Trading of Xeris Biopharma

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Corient Private Wealth LLC acquired a new position in Xeris Biopharma during the 4th quarter valued at approximately $84,000. VARCOV Co. purchased a new stake in shares of Xeris Biopharma during the fourth quarter valued at $243,000. Virtus Investment Advisers LLC increased its position in shares of Xeris Biopharma by 44.1% in the 4th quarter. Virtus Investment Advisers LLC now owns 37,102 shares of the company’s stock valued at $291,000 after acquiring an additional 11,358 shares during the period. Millennium Management LLC grew its stake in Xeris Biopharma by 63.7% during the 4th quarter. Millennium Management LLC now owns 859,051 shares of the company’s stock valued at $6,744,000 after purchasing an additional 334,302 shares during the last quarter. Finally, Man Group plc acquired a new position in shares of Xeris Biopharma in the fourth quarter valued at about $375,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.